Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J Oldgren, A Budaj, CB Granger, Y Khder… - European heart …, 2011 - academic.oup.com
Aim After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …
被引用次数：735 相关文章

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J Oldgren, A Budaj, CB Granger, Y Khder… - European Heart …, 2011 - swepub.kb.se
Aim After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …
[PDF] researchgate.net

[PDF][PDF] Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J Oldgren, A Budaj, CB Granger, Y Khder… - European Heart …, 2011 - researchgate.net
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet
therapy: a randomized, double-blind, phase Page 1 …

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J Oldgren, A Budaj, CB Granger… - European …, 2011 - researchinformation.amsterdamumc …
After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …

[引用][C] Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J OLDGREN, A BUDAJ, CB GRANGER… - European heart …, 2011 - pascal-francis.inist.fr
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet
therapy: a randomized, double-blind, phase II trial CNRS Inist Pascal-Francis CNRS Pascal …
[PDF] academia.edu

[PDF][PDF] Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J Oldgren, A Budaj, CB Granger, Y Khder… - European Heart …, 2011 - academia.edu
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet
therapy: a randomized, double-blind, phase Page 1 …

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

J Oldgren, A Budaj, CB Granger, Y Khder… - European Heart …, 2011 - europepmc.org
Aim After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J Oldgren, A Budaj, CB Granger… - European heart …, 2011 - pubmed.ncbi.nlm.nih.gov
Aim After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …

[引用][C] Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J Oldgren - (No Title), 2011 - cir.nii.ac.jp

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

J Oldgren, A Budaj, CB Granger, Y Khder… - European Heart …, 2011 - diva-portal.org
Aim After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …